NCT02585843
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
See it on ClinicalTrials.gov ↗20 people
55%
45%
11 womenmiddle line = equal numbers9 men
- Phase
- PHASE2, PHASE3
- Paid for by
- Columbia University
- Finished
- 2017-03-31
- Health conditions
- Heart Failure
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 62.6 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Hispanic / Latina 65% · Black / African American 30% · White 5%
Women left out
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Primary liver disease resulted in cirrhosis or abnormal liver function tests (transaminases and alkaline phosphatase levels 3 times the upper limit of normal”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Acute coronary syndromes or unstable angina within the past 4 weeks”
- No cancer
Women with current or past cancer were turned away.
“Acute malignancy”
Study titles and rules are shown in their original English.